SEOUL -- South Korean drugmaker SK Biopharmaceuticals started the run-in to its $800 million initial public offering by offering more details of its development pipeline, saying it would begin clinical trials of a cancer treatment next year.
The share offering by SK Biopharmaceutical is expected to be the biggest in South Korea for three years. It comes as the country's pharmaceutical industry has gained global attention thanks to South Korea's swift response to the coronavirus outbreak.
